The data from TRACERx should be applicable to other types, so it will be interesting to compare data from them to this company, PACT Pharma, and IOVA.
As for blood cancers, sometime this year XBIO will file an IND for its cell therapy. The goal is to develop CAR-T products targeting the unique B-cell receptor on the surface of an individual patient's malignant cancer cells for the treatment of lymphomas https://advances.sciencemag.org/content/4/11/eaau4580
News 
Market Data 
Discover 
